Ratings XOMA Corporation Nasdaq

Equities

XOMAP

US98419J3059

Market Closed - Nasdaq Other stock markets 01:30:01 2024-07-03 pm EDT			5-day change	1st Jan Change
26.34 ^USD	+0.57%		+3.44%	+3.66%

Jul. 01	XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index	CI
Jul. 01	XOMA Corporation(NasdaqGM:XOMA) added to Russell Microcap Growth Index	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past twelve months, EPS forecast has been revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XOMA CORPORATION	+3.66%	301M	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B	B+
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B	B+
ARGENX SE	+17.73%	25.93B	B
BIONTECH SE	-24.33%	19.27B	B+
GENMAB A/S	-19.35%	16.01B	A-
BEIGENE, LTD.	-17.95%	15.66B	B
WUXI APPTEC CO., LTD.	-48.32%	14.89B	A-
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B	C+
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes